Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | ADH1C | P00326 | 2/20 | 0.35 |
| ▸ | ADH4 | P08319 | 1/20 | 0.35 |
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | MGLL | Q99685 | 2/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | PHGDH | O43175 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL502635 | 0.85 | HSD17B10 (0.31) | ADH1AADH1CADH4THRATHRB | |
| SCHEMBL27944708 | 0.80 | CYP3A4 (0.38) | ADH1ATHRATHRBMEN1KMT2A | |
| SCHEMBL503798 | 0.80 | MEN1 (0.35) | ADH1ACA12CA1CA2CA9 | |
| SCHEMBL11440510 | 0.80 | CA12 (0.37) | ADH1ACA12CA1CA2CA9 | |
| SCHEMBL4457282 | 0.80 | GAA (0.44) | ADH1AADH1CMEN1KMT2ACYP1A2 | |
| SCHEMBL28866726 | 0.79 | ADH1A (0.38) | ADH1AADH1CMEN1KMT2ACYP1A2 | |
| SCHEMBL11494864 | 0.78 | GAA (0.43) | ADH1AADH1CMEN1KMT2ACYP1A2 | |
| SCHEMBL28805215 | 0.78 | MGLL (0.39) | ADH1ACA12CA1CA2CA9 | |
| SCHEMBL28827497 | 0.78 | MGLL (0.39) | ADH1ACA12CA1CA2CA9 | |
| SCHEMBL28827023 | 0.78 | MGLL (0.39) | ADH1ACA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3311843-A1 | COMPOSITIONS COMPRISING DITHIOCARBAMATE AND CYCLODEXTRIN | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts (DE) | 2018-04-25 | — | — | EP | claimed |
| US-20070232692-A1 | Method of Treating Cancer Using Dithiocarbamate Derivatives | THE UNIVERSITY OF UTAH | 2007-10-04 | — | — | US | claimed |
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2023-05-04 | — | — | US | disclosed |
| US-11541027-B2 | Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2023-01-03 | — | — | US | disclosed |
| US-11026914-B2 | Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-06-08 | — | — | US | disclosed |
| EP-3125920-B1 | DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL OR DIBROMODULCITOL TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER | DEL MAR PHARMACEUTICALS (CA) | 2020-12-23 | — | — | EP | disclosed |
| US-20190269646-A9 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2019-09-05 | — | — | US | disclosed |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2019-06-20 | — | — | US | disclosed |
| US-20190175541-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2019-06-13 | — | — | US | disclosed |
| US-20190091195-A1 | USE OF DIANHYDROGALACTITOL AND DERIVATIVES THEREOF IN THE TREATMENT OF GLIOBLASTOMA, LUNG CANCER, AND OVARIAN CANCER | DEL MAR PHARMACEUTICALS (CA) | 2019-03-28 | — | — | US | disclosed |
| US-20190015379-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF, TOGETHER WITH RADIATION, TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME AND SUPPRESS PROLIFERATION OF CANCER STEM CELLS | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2019-01-17 | — | — | US | disclosed |
| US-5294430-A | Side effect reduction of antitumor agents | UNIVERSITY OF ROCHESTER (US) | 1994-03-15 | — | — | US | disclosed |
| US-5187193-A | Administering dithiocarbamate derivative | UNIVERSITY OF ROCHESTER (US) | 1993-02-16 | — | — | US | disclosed |
| EP-0433393-A4 | TREATMENT OF DAMAGED BONE MARROW AND DOSAGE UNITS THEREFOR | — | 1992-01-15 | — | — | EP | disclosed |
| US-5035878-A | Reversing bone marrow damage resulting from chemotherapy | UNIVERSITY OF ROCHESTER (US) | 1991-07-30 | — | — | US | disclosed |
| EP-0433393-A1 | TREATMENT OF DAMAGED BONE MARROW AND DOSAGE UNITS THEREFOR. | UNIV ROCHESTER (US) | 1991-06-26 | — | — | EP | disclosed |
| US-4938949-A | Combatting side effects of anticancer drugs with dithiocarbamates | UNIVERSITY OF NEW YORK (US) | 1990-07-03 | — | — | US | disclosed |
| WO-1990002550-A1 | TREATMENT OF DAMAGED BONE MARROW AND DOSAGE UNITS THEREFOR | UNIVERSITY OF ROCHESTER (US) | 1990-03-22 | — | — | WO | disclosed |
| US-4594238-A | Administering platinum compound; then platimun binding compound | REGENTS OF UNIVERSITY OF MINNESOTA (US) | 1986-06-10 | — | — | US | disclosed |
| US-4581224-A | ANTITUMOR, ANTRICARCINOGENIC AGENTS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1986-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | ADH1A 2944/4885CA12 1360/4885CA1 1837/4885 |
| US-20190175541-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | ADH1A 3327/4885CA12 1133/4885CA1 725/4885 |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | ADH1A 3327/4885CA12 1133/4885CA1 725/4885 |
| US-20190015379-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF, TOGETHER WITH RADIATION, TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME AND SUPPRESS PROLIFERATION OF CANCER STEM CELLS | MGMT, DCLRE1A, DNMT1 | ADH1A 196/4885CA12 1160/4885CA1 2097/4885 |
| US-20190269646-A9 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES | DNMT1, MGMT, DCK | ADH1A 1265/4885CA12 486/4885CA1 131/4885 |
| US-20190091195-A1 | USE OF DIANHYDROGALACTITOL AND DERIVATIVES THEREOF IN THE TREATMENT OF GLIOBLASTOMA, LUNG CANCER, AND OVARIAN CANCER | DDOST, DCLRE1A, OGG1 | ADH1A 1030/4885CA12 203/4885CA1 343/4885 |
| US-20070232692-A1 | Method of Treating Cancer Using Dithiocarbamate Derivatives | TST, HCCS, SERPINC1 | ADH1A 2667/4885CA12 120/4885CA1 58/4885 |
| US-11026914-B2 | Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor | DDOST, DAD1, PHGDH | ADH1A 494/4885CA12 104/4885CA1 165/4885 |
| US-11541027-B2 | Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases | DNMT1, MGMT, DCK | ADH1A 1265/4885CA12 486/4885CA1 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.